Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer

Abstract

Background: Until recently there has been no effective therapy for patients with relapsed ovarian carcinoma following standard platinum based chemotherapy. Paclitaxel has recently been approved for clinical use in this malignancy. Aims: To evaluate the objective response rate and toxicity of paclitaxel in patients with relapsed ovarian cancer. Methods: Paclitaxel was given on an outpatient basis as a three hour infusion every 21 days for a maximum often cycles to 72 patients with advanced ovarian cancer previously treated with at least one platinum containing regimen. The starting dose was either 175 mg/m2 (patients with one or two prior chemotherapy regimens) or 135 mg/m2 (three previous re..